Ginkgo Bioworks Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M |
| Operating income | -$315.3M | -$559.8M | -$864.4M | -$2.2B | -$1.8B |
| Operating expenses | $485.4M | $786.8M | $1.1B | $2.7B | $2.1B |
| Cash from operations | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M |
| Capital expenditure | $7.7M | $62.5M | $40.8M | $52.3M | $56.5M |
| Free cash flow | -$178.7M | -$382.1M | -$336.3M | -$304.5M | -$310.3M |
| Share repurchases | — | — | $0 | $0 | $25.0M |
| Impairments | $0 | $4.8M | $0 | $0 | $0 |
| Total assets | $1.1B | $1.4B | $1.7B | $2.5B | $2.1B |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803.0M | $503.6M |
Shares outstanding 65.3M · Free float 87.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.